AnnJi Advances AJ201 into Phase 3 Trial for Kennedy’s Disease
AnnJi moves AJ201 (rosolutamide) into the pivotal Phase 3 ROMA-KD trial for spinal and bulbar muscular atrophy, also called Kennedy disease.
Tag: AnnJi Pharmaceutical
Read More